Orphazyme AS (OCSE:ORPHA) ROCE % : -89.06% (As of Jun. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Orphazyme AS ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Orphazyme AS's annualized ROCE % for the quarter that ended in Jun. 2022 was -89.06%.

Orphazyme AS ROCE % Historical Data

The historical data trend for Orphazyme AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS ROCE % Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

ROCE %

Get a 7-Day Free Trial

-41.38

-46.27

-134.44

-161.18

-177.72

Orphazyme AS Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
ROCE %	Get a 7-Day Free Trial									-146.67	-124.13	-26.65	-908.95	-89.06

Orphazyme AS ROCE % Calculation

Orphazyme AS's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	-622.022	/	( ( (822.493 - 166.627)	+	(173.229 - 129.092) )	/ 2 )
	=	-622.022	/	( (655.866	+	44.137)	/ 2 )
	=	-622.022	/	350.0015
	=	-177.72 %

Orphazyme AS's ROCE % of for the quarter that ended in Jun. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2022 )		(Q: Dec. 2021 )		(Q: Jun. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2022 )		(Q: Dec. 2021 )		(Q: Jun. 2022 )
	=	-54.478	/	( ( (173.229 - 129.092)	+	(93.589 - 15.384) )	/ 2 )
	=	-54.478	/	( ( 44.137	+	78.205 )	/ 2 )
	=	-54.478	/	61.171
	=	-89.06 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2022) EBIT data.

Orphazyme AS (OCSE:ORPHA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Orphazyme AS ROCE % Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS (OCSE:ORPHA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (OCSE:ORPHA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (OCSE:ORPHA) Headlines

No Headlines